Patients diagnosed clinically as having PAH with biallelic EIF2AK4 variants exhibited a shorter survival time from diagnosis compared with the BMPR2 variant carriers (p < 0.0001 for log-rank test, Fig. 1). This evidence concerns the gene EIF2AK4 and pulmonary arterial hypertension.